Fisetin, a 3,7,3′,4′-Tetrahydroxyflavone Inhibits the PI3K/Akt/mTOR and MAPK Pathways and Ameliorates Psoriasis Pathology in 2D and 3D Organotypic Human Inflammatory Skin Models

Psoriasis is a chronic immune-mediated skin disease that involves the interaction of immune and skin cells, and is characterized by cytokine-driven epidermal hyperplasia, deviant differentiation, inflammation, and angiogenesis. Because the available treatments for psoriasis have significant limitations, dietary products are potential natural sources of therapeutic molecules, which can repair the molecular defects associated with psoriasis and could possibly be developed for its management. Fisetin (3,7,3′,4′-tetrahydroxyflavone), a phytochemical naturally found in pigmented fruits and vegetables, has demonstrated proapoptotic and antioxidant effects in several malignancies. This study utilized biochemical, cellular, pharmacological, and tissue engineering tools to characterize the effects of fisetin on normal human epidermal keratinocytes (NHEKs), peripheral blood mononuclear cells (PBMC), and CD4+ T lymphocytes in 2D and 3D psoriasis-like disease models. Fisetin treatment of NHEKs dose- and time-dependently induced differentiation and inhibited interleukin-22-induced proliferation, as well as activation of the PI3K/Akt/mTOR pathway. Fisetin treatment of TNF-α stimulated NHEKs also significantly inhibited the activation of p38 and JNK, but had enhanced effect on ERK1/2 (MAPK). In addition, fisetin treatment significantly decreased the secretion of Th1/Th-17 pro-inflammatory cytokines, particularly IFN-γ and IL-17A by 12-O-tetradecanolylphorbol 13-acetate (TPA)-stimulated NHEKs and anti-CD3/CD28-activated human PBMCs. Furthermore, we established the in vivo relevance of fisetin functions, using a 3D full-thickness human skin model of psoriasis (FTRHSP) that closely mimics in vivo human psoriatic skin lesions. Herein, fisetin significantly ameliorated psoriasis-like disease features, and decreased the production of IL-17 by CD4+ T lymphocytes co-cultured with FTRHSP. Collectively, our data identify the prodifferentiative, antiproliferative, and anti-inflammatory effects of fisetin, via modulation of the PI3K-Akt-mTOR and p38/JNK pathways and the production of cytokines in 2D and 3D human skin models of psoriasis. These results suggest that fisetin has a great potential to be developed as an effective and inexpensive agent for the treatment of psoriasis and other related inflammatory skin disorders.

[1]  Shun-Fa Yang,et al.  Fisetin Suppresses the Proliferation and Metastasis of Renal Cell Carcinoma through Upregulation of MEK/ERK-Targeting CTSS and ADAM9 , 2019, Cells.

[2]  R. Sabat,et al.  T cell pathology in skin inflammation , 2019, Seminars in Immunopathology.

[3]  S. Hintermann,et al.  Antagonizing Retinoic Acid-Related-Orphan Receptor Gamma Activity Blocks the T Helper 17/Interleukin-17 Pathway Leading to Attenuated Pro-inflammatory Human Keratinocyte and Skin Responses , 2019, Front. Immunol..

[4]  C. Buerger Epidermal mTORC1 Signaling Contributes to the Pathogenesis of Psoriasis and Could Serve as a Therapeutic Target , 2018, Front. Immunol..

[5]  S. Chiu,et al.  Fisetin targets YB-1/RSK axis independent of its effect on ERK signaling: insights from in vitro and in vivo melanoma models , 2018, Scientific Reports.

[6]  W. Boehncke,et al.  The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond , 2018, Front. Immunol..

[7]  S. Mousa,et al.  Chitosan-based nanoformulated (−)-epigallocatechin-3-gallate (EGCG) modulates human keratinocyte-induced responses and alleviates imiquimod-induced murine psoriasiform dermatitis , 2018, International journal of nanomedicine.

[8]  M. Gilliet,et al.  Psoriasis: from Pathogenesis to Targeted Therapies , 2018, Clinical Reviews in Allergy & Immunology.

[9]  M. Haussler,et al.  Bioactive Dietary VDR Ligands Regulate Genes Encoding Biomarkers of Skin Repair That Are Associated with Risk for Psoriasis , 2018, Nutrients.

[10]  A. Abdou,et al.  C-Jun expression in lichen planus, psoriasis, and cutaneous squamous cell carcinoma, an immunohistochemical study , 2018, Journal of immunoassay & immunochemistry.

[11]  K. Satyshur,et al.  Dual Inhibition of PI3K/Akt and mTOR by the Dietary Antioxidant, Delphinidin, Ameliorates Psoriatic Features In Vitro and in an Imiquimod-Induced Psoriasis-Like Disease in Mice. , 2017, Antioxidants & redox signaling.

[12]  V. Adhami,et al.  Exploring the molecular targets of dietary flavonoid fisetin in cancer. , 2016, Seminars in cancer biology.

[13]  V. Adhami,et al.  Upregulation of PI3K/AKT/mTOR, FABP5 and PPARβ/δ in Human Psoriasis and Imiquimod-induced Murine Psoriasiform Dermatitis Model. , 2016, Acta dermato-venereologica.

[14]  R. Kümmerli,et al.  Beyond killing , 2016, Evolution, medicine, and public health.

[15]  A. Bowcock,et al.  The immunogenetics of Psoriasis: A comprehensive review. , 2015, Journal of autoimmunity.

[16]  Moonil Kim,et al.  Fisetin, a dietary flavonoid, induces apoptosis of cancer cells by inhibiting HSF1 activity through blocking its binding to the hsp70 promoter. , 2015, Carcinogenesis.

[17]  C. Elmets,et al.  Prodifferentiation, Anti-Inflammatory and Antiproliferative Effects of Delphinidin, a Dietary Anthocyanidin, in a Full-Thickness Three-Dimensional Reconstituted Human Skin Model of Psoriasis , 2015, Skin Pharmacology and Physiology.

[18]  W. Bollag,et al.  The Antipsoriatic Agent Monomethylfumarate Has Antiproliferative, Prodifferentiative, and Anti-Inflammatory Effects on Keratinocytes , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[19]  L. Skov,et al.  Comparison of long‐term drug survival and safety of biologic agents in patients with psoriasis vulgaris , 2015, The British journal of dermatology.

[20]  Xiran Lin,et al.  Phosphoinositide-3 kinase/protein kinase-B/mammalian target of rapamycin pathway in psoriasis pathogenesis. A potential therapeutic target? , 2014, Acta dermato-venereologica.

[21]  V. Adhami,et al.  Fisetin inhibits human melanoma cell growth through direct binding to p70S6K and mTOR: findings from 3-D melanoma skin equivalents and computational modeling. , 2014, Biochemical pharmacology.

[22]  S. Toda,et al.  Periostin controls keratinocyte proliferation and differentiation by interacting with the paracrine IL-1α/IL-6 loop. , 2014, The Journal of investigative dermatology.

[23]  Sanghee Kim,et al.  Phytosphingosine derivatives ameliorate skin inflammation by inhibiting NF-κB and JAK/STAT signaling in keratinocytes and mice. , 2014, The Journal of investigative dermatology.

[24]  J. Schalkwijk,et al.  Crosstalk between keratinocytes and T cells in a 3D microenvironment: a model to study inflammatory skin diseases. , 2014, The Journal of investigative dermatology.

[25]  E. Haufe,et al.  Efficacy and safety of systemic treatments for moderate‐to‐severe psoriasis: meta‐analysis of randomized controlled trials , 2014, The British journal of dermatology.

[26]  M. Ekor,et al.  The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety , 2014, Front. Pharmacol..

[27]  Ying Xiong,et al.  Suppressive effects of fisetin on mice T lymphocytes in vitro and in vivo. , 2013, The Journal of surgical research.

[28]  H. Mukhtar,et al.  Protective Effect of Tropical Highland Blackberry Juice (Rubus adenotrichos Schltdl.) Against UVB‐Mediated Damage in Human Epidermal Keratinocytes and in a Reconstituted Skin Equivalent Model , 2013, Photochemistry and photobiology.

[29]  Hasan Mukhtar,et al.  Inhibition of Akt/mTOR signaling by the dietary flavonoid fisetin. , 2013, Anti-cancer agents in medicinal chemistry.

[30]  S. Yuspa,et al.  Opposing functions of psoriasin (S100A7) and koebnerisin (S100A15) in epithelial carcinogenesis. , 2013, Current opinion in pharmacology.

[31]  H. Mukhtar,et al.  Fisetin: a dietary antioxidant for health promotion. , 2013, Antioxidants & redox signaling.

[32]  C. Elmets,et al.  Fisetin inhibits growth, induces G2/M arrest and apoptosis of human epidermoid carcinoma A431 cells: role of mitochondrial membrane potential disruption and consequent caspases activation , 2013, Experimental dermatology.

[33]  R. Pouliot,et al.  Promising New Treatments for Psoriasis , 2013, TheScientificWorldJournal.

[34]  R. Ray,et al.  1α,25-Dihydroxyvitamin-D3-3-bromoacetate regulates AKT/mTOR signaling cascades: a therapeutic agent for psoriasis. , 2013, The Journal of investigative dermatology.

[35]  David J Newman,et al.  Natural products: a continuing source of novel drug leads. , 2013, Biochimica et biophysica acta.

[36]  R. Eckert,et al.  AP1 Transcription Factors in Epidermal Differentiation and Skin Cancer , 2013, Journal of skin cancer.

[37]  V. Adhami,et al.  Delphinidin, a dietary antioxidant, induces human epidermal keratinocyte differentiation but not apoptosis: studies in submerged and three‐dimensional epidermal equivalent models , 2013, Experimental dermatology.

[38]  W. Liao,et al.  Phototherapy in Psoriasis: A Review of Mechanisms of Action , 2013, Journal of cutaneous medicine and surgery.

[39]  N. Jarjour,et al.  Human eosinophils release IL‐1ß and increase expression of IL‐17A in activated CD4+ T lymphocytes , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[40]  V. Adhami,et al.  Dietary flavonoid fisetin: a novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management. , 2012, Biochemical pharmacology.

[41]  S. Raychaudhuri,et al.  IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade. , 2012, Cytokine.

[42]  U. Mrowietz,et al.  Triptolide in the treatment of psoriasis and other immune-mediated inflammatory diseases. , 2012, British journal of clinical pharmacology.

[43]  J. M. Cunha,et al.  Tumor necrosis factor-alpha and the cytokine network in psoriasis. , 2012, Anais brasileiros de dermatologia.

[44]  J. Krueger,et al.  Putting together the psoriasis puzzle: an update on developing targeted therapies , 2012, Disease Models & Mechanisms.

[45]  Jennifer Villaseñor-Park,et al.  Psoriasis: Evolving treatment for a complex disease , 2012, Cleveland Clinic Journal of Medicine.

[46]  T. Ruzicka,et al.  Vitamin D analog calcipotriol suppresses the Th17 cytokine-induced proinflammatory S100 "alarmins" psoriasin (S100A7) and koebnerisin (S100A15) in psoriasis. , 2012, The Journal of investigative dermatology.

[47]  D. Sabatini,et al.  mTOR Signaling in Growth Control and Disease , 2012, Cell.

[48]  H. Mukhtar,et al.  Dual inhibition of phosphatidylinositol 3‐kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin , 2012, International journal of cancer.

[49]  W. Wong,et al.  Fisetin, a bioactive flavonol, attenuates allergic airway inflammation through negative regulation of NF-κB. , 2012, European journal of pharmacology.

[50]  T. Mabuchi,et al.  Epidermal CCR6+ γδ T Cells Are Major Producers of IL-22 and IL-17 in a Murine Model of Psoriasiform Dermatitis , 2011, The Journal of Immunology.

[51]  P. Vandenabeele,et al.  Caspase-14 is required for filaggrin degradation to natural moisturizing factors in the skin. , 2011, The Journal of investigative dermatology.

[52]  H. Törmä,et al.  Chemical chaperones protect epidermolysis bullosa simplex keratinocytes from heat stress-induced keratin aggregation: involvement of heat shock proteins and MAP kinases. , 2011, The Journal of investigative dermatology.

[53]  H. Mukhtar,et al.  Inhibition of human melanoma cell growth by the dietary flavonoid fisetin is associated with disruption of Wnt/β-catenin signaling and decreased Mitf levels. , 2011, The Journal of investigative dermatology.

[54]  V. Adhami,et al.  Keratin gene mutations in disorders of human skin and its appendages. , 2011, Archives of biochemistry and biophysics.

[55]  M. Wittmann,et al.  Primary human keratinocytes efficiently induce IL‐1‐dependent IL‐17 in CCR6+ T cells , 2010, Experimental dermatology.

[56]  C. Griffiths,et al.  Comparing biological therapies in psoriasis: implications for clinical practice , 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.

[57]  A. Bowcock,et al.  Psoriasis genetics: breaking the barrier. , 2010, Trends in genetics : TIG.

[58]  J. Krueger,et al.  New insights in the immunologic basis of psoriasis. , 2010, Seminars in cutaneous medicine and surgery.

[59]  Frank O. Nestle,et al.  Skin immune sentinels in health and disease , 2009, Nature Reviews Immunology.

[60]  J. Farber,et al.  CCR6 is required for IL-23-induced psoriasis-like inflammation in mice. , 2009, The Journal of clinical investigation.

[61]  Frank O. Nestle,et al.  Mechanisms of Disease: Psoriasis. , 2009 .

[62]  C. Sutherland,et al.  Filaggrin in the frontline: role in skin barrier function and disease , 2009, Journal of Cell Science.

[63]  H. Volk,et al.  IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-γ are not , 2009, Journal of Molecular Medicine.

[64]  G. Hannon,et al.  Ezh2 Orchestrates Gene Expression for the Stepwise Differentiation of Tissue-Specific Stem Cells , 2009, Cell.

[65]  Lisa C. Zaba,et al.  Resident and "inflammatory" dendritic cells in human skin. , 2009, The Journal of investigative dermatology.

[66]  H. Uchi,et al.  Activation of the mammalian target of rapamycin signalling pathway in epidermal tumours and its correlation with cyclin‐dependent kinase 2 , 2009, The British journal of dermatology.

[67]  Lisa C. Zaba,et al.  Th17 cytokines interleukin (IL)‐17 and IL‐22 modulate distinct inflammatory and keratinocyte‐response pathways , 2008, The British journal of dermatology.

[68]  S. Yuspa,et al.  Chemotactic Activity of S100A7 (Psoriasin) Is Mediated by the Receptor for Advanced Glycation End Products and Potentiates Inflammation with Highly Homologous but Functionally Distinct S100A151 , 2008, The Journal of Immunology.

[69]  H. Mukhtar,et al.  Fisetin, a novel dietary flavonoid, causes apoptosis and cell cycle arrest in human prostate cancer LNCaP cells. , 2008, Carcinogenesis.

[70]  E. Wagner,et al.  Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease , 2008, Arthritis research & therapy.

[71]  Khusru Asadullah,et al.  Immunopathogenesis of psoriasis , 2007, Experimental dermatology.

[72]  James T. Elder,et al.  Mouse models of psoriasis. , 2007, The Journal of investigative dermatology.

[73]  P. Vandenabeele,et al.  Caspase-14 protects against epidermal UVB photodamage and water loss , 2007, Nature Cell Biology.

[74]  S. MacNeil,et al.  Transglutaminase inhibitors induce hyperproliferation and parakeratosis in tissue‐engineered skin , 2007, The British journal of dermatology.

[75]  S. Esnault,et al.  The Peptidyl-Prolyl Isomerase Pin1 Regulates Granulocyte-Macrophage Colony-Stimulating Factor mRNA Stability in T Lymphocytes1 , 2006, The Journal of Immunology.

[76]  C. Elmets An animal model of psoriasis in mice deficient in epidermal Jun proteins. , 2006, Archives of dermatology.

[77]  Ying Wang,et al.  A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17 , 2005, Nature Immunology.

[78]  O. Arican,et al.  Serum Levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in Patients With Active Psoriasis and Correlation With Disease Severity , 2005, Mediators of inflammation.

[79]  E. Wagner,et al.  Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins , 2005, Nature.

[80]  Rainer Schmidt,et al.  The cornified envelope: a model of cell death in the skin , 2005, Nature Reviews Molecular Cell Biology.

[81]  R. Eckert,et al.  Transglutaminase function in epidermis. , 2005, The Journal of investigative dermatology.

[82]  T. Mcclanahan,et al.  IL-23 drives a pathogenic T cell population that induces autoimmune inflammation , 2005, The Journal of experimental medicine.

[83]  P. Vandenabeele,et al.  Vitamin D3 induces caspase-14 expression in psoriatic lesions and enhances caspase-14 processing in organotypic skin cultures. , 2004, The American journal of pathology.

[84]  T. Hirano,et al.  Fisetin, a flavonol, inhibits TH2-type cytokine production by activated human basophils. , 2003, The Journal of allergy and clinical immunology.

[85]  A. Gröne Keratinocytes and cytokines. , 2002, Veterinary immunology and immunopathology.

[86]  G. Melino,et al.  Expression of transglutaminase 5 in normal and pathologic human epidermis. , 2002, The Journal of investigative dermatology.

[87]  Y. Arai,et al.  Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol concentration. , 2000, The Journal of nutrition.

[88]  J. Travers,et al.  Acute keratinocyte damage stimulates platelet-activating factor production , 2000, Archives of Dermatological Research.

[89]  A. Dorner,et al.  Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. , 1999, The Journal of clinical investigation.

[90]  W. Busse,et al.  The effect of segmental bronchoprovocation with allergen on airway lymphocyte function. , 1997, American journal of respiratory and critical care medicine.

[91]  J. Kieffer,et al.  Inflammatory skin disease in transgenic mice that express high levels of interleukin 1 alpha in basal epidermis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[92]  C. Elmets,et al.  Fisetin Inhibits UVB‐induced Cutaneous Inflammation and Activation of PI3K/AKT/NFκB Signaling Pathways in SKH‐1 Hairless Mice , 2015, Photochemistry and photobiology.

[93]  R. Romiti,et al.  Ten years on: the impact of biologics on the practice of dermatology. , 2015, Dermatologic clinics.